The iLite® VEGF Assay Ready Cells can be used for the quantification of VEGF activity, VEGF inhibitor activity and for determination of neutralizing antibodies against VEGF inhibitors in human serum. Vascular Endothelial Growth Factor (VEGF) is a signalling protein which is involved in both normal vascular growth and pathological angiogenesis. Without angiogenesis, growth of solid tumours would be limited by oxygen supply. Tumours which express VEGF can overcome this limitation and are thus able to grow and metastasize. For this reason, different anti-cancer therapies targeting VEGF have emerged, e.g. a humanized anti-VEGF antibody such as bevacizumab (AvastinTM, Genentech) is currently widely used as a first-line therapy for colorectal cancer.